Hauke Schneider

Hauke Schneider

Auto-generated profile, based on publicly available information

Hauke Schneider

Department of Neurology, University Hospital Augsburg, Augsburg, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EJEric Jüttler
Eric Jüttler
AUAndreas Unterberg
Andreas Unterberg
JWJohannes Woitzik
Johannes Woitzik
JBJulian Bösel
Julian Bösel
HAHemasse Amiri
Hemasse Amiri
WHWerner Hacke
Werner Hacke
Early decompressive hemicraniectomy reduces mortality without increasing the risk of very severe disability among patients 60 years of age or younger with complete or subtotal space-occupying middle-cerebral-artery infarction. Its benefit in older patients is uncertain. We randomly assigned 112 patients 61 years of age or older (median, 70 years; range, 61 to 82) with malignant middle-cerebral-artery infarction to either conservative treatment in the intensive care unit (the control group) or hemicraniectomy (the hemicraniectomy group); assignments were made within 48 hours after the onset of symptoms. The primary end point was survival without severe disability (defined by a score of 0 to 4 on the modified Rankin scale, which ranges from 0 [no symptoms] to 6 [death]) 6 months after randomization. Hemicraniectomy improved the primary outcome; the proportion of patients who survived without severe disability was 38% in the hemicraniectomy group, as compared with 18% in the control group (odds ratio, 2.91; 95% confidence interval, 1.06 to 7.49; P=0.04). This difference resulted from lower mortality in the surgery group (33% vs. 70%). No patients had a modified Rankin scale score of 0 to 2 (survival with no disability or slight disability); 7% of patients in the surgery group and 3% of patients in the control group had a score of 3 (moderate disability); 32% and 15%, respectively, had a score of 4 (moderately severe disability [requirement for assistance with most bodily needs]); and 28% and 13%, respectively, had a score of 5 (severe disability). Infections were more frequent in the hemicraniectomy group, and herniation was more frequent in the control group. Hemicraniectomy increased survival without severe disability among patients 61 years of age or older with a malignant middle-cerebral-artery infarction. The majority of survivors required assistance with most bodily needs. (Funded by the Deutsche Forschungsgemeinschaft; DESTINY II Current Controlled Trials number, ISRCTN21702227.)

24 February 2015 in JAMA
Verified
Journal Article
Open access
PDF file
JKJoji B. Kuramatsu
Joji B. Kuramatsu
SGStefan T. Gerner
Stefan T. Gerner
PSPeter D. Schellinger
Peter D. Schellinger
JGJörg Glahn
Jörg Glahn
MEMatthias Endres
Matthias Endres
HHHagen B. Huttner
Hagen B. Huttner
The prevalence of cardiovascular diseases requiring long-term oral anticoagulation (OAC) is increasing, notably the incidence and prevalence of atrial fibrillation.1,2 The most significant complication of OAC is intracerebral hemorrhage (ICH).3 Based on OAC-induced coagulopathy, large hematoma volumes and increased rates of hematoma enlargement are characteristics of OAC-associated ICH (OAC-ICH) and contribute to an even higher mortality when compared with ischemic stroke or primary ICH.4-7

10 April 2025 in New England Journal of Medicine
Verified
Journal Article
Closed access
MGMayank Goyal
Mayank Goyal
JOJohanna M Ospel
Johanna M Ospel
AGAravind Ganesh
Aravind Ganesh
DDDar Dowlatshahi
Dar Dowlatshahi
DVDavid Volders
David Volders
EIESCAPE-MeVO Investigators
ESCAPE-MeVO Investigators
Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective, randomized, open-label trial with blinded outcome evaluation, we assigned patients with acute ischemic stroke due to medium-vessel occlusion who presented within 12 hours from the time that they were last known to be well and who had favorable baseline noninvasive brain imaging to receive EVT plus usual care or usual care alone. The primary outcome was the modified Rankin scale score (range, 0 [no symptoms] to 6 [death]) at 90 days, reported as the percentage of patients with a score of 0 or 1. A total of 530 patients from five countries were enrolled between April 2022 and June 2024, with 255 patients assigned to the EVT group and 275 to the usual-care group. Most patients (84.7%) had primary occlusions in a middle-cerebral-artery branch. A modified Rankin scale score of 0 or 1 at 90 days occurred in 106 of 255 patients (41.6%) in the EVT group and in 118 of 274 (43.1%) in the usual-care group (adjusted rate ratio, 0.95; 95% confidence interval [CI], 0.79 to 1.15; P = 0.61). Mortality at 90 days was 13.3% in the EVT group and 8.4% in the usual-care group (adjusted hazard ratio, 1.82; 95% CI, 1.06 to 3.12). Symptomatic intracranial hemorrhage occurred in 14 of 257 patients (5.4%) in the EVT group and in 6 of 272 (2.2%) in the usual-care group. Endovascular treatment for acute ischemic stroke due to medium-vessel occlusion within 12 hours did not lead to better outcomes at 90 days than usual care. (Funded by the Canadian Institutes for Health Research and Medtronic; ESCAPE-MeVO ClinicalTrials.gov number, NCT05151172.).

8 October 2019 in JAMA
Verified
Journal Article
Open access
PDF file
JKJoji B. Kuramatsu
Joji B. Kuramatsu
ABAlessandro Biffi
Alessandro Biffi
SGStefan T. Gerner
Stefan T. Gerner
JSJochen A. Sembill
Jochen A. Sembill
MSMaximilian I. Sprügel
Maximilian I. Sprügel
HHHagen B. Huttner
Hagen B. Huttner
Based on an age-adjusted incidence-rate for intracerebral hemorrhage (ICH) in high-income countries for the year 2010, it was estimated that cerebellar ICH affects approximately 35 000 patients annually within the European Union and the United States.1-3 There have not been randomized trials of treatment interventions for patients with cerebellar ICH. Since 1984, surgical hematoma evacuation has been the preferred treatment approach, specifically in patients with larger hematomas and intraventricular involvement, given increased risk for brainstem compression and herniation.4-8 However, evidence on the association between surgical hematoma evacuation and clinical outcomes after cerebellar ICH has been limited to small observational studies.9,10 International guidelines including the American Heart Association/American Stroke Association guideline recommend surgical hematoma evacuation for cerebellar ICH with diameter greater than 3 cm to improve outcome; however, definite evidence to validate or refute this recommendation is currently not available.4,9,10 As a result, there is no commonly accepted management strategy for cerebellar ICH and no general agreement regarding whether, when, and how these patients should undergo surgical intervention.8,11 The purpose of this study was to assess the association of surgical hematoma evacuation with functional outcome and mortality in patients with cerebellar ICH.

24 January 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
SGStefan T. Gerner
Stefan T. Gerner
JKJoji B. Kuramatsu
Joji B. Kuramatsu
JSJochen A. Sembill
Jochen A. Sembill
MSMaximilian I. Sprügel
Maximilian I. Sprügel
MEMatthias Endres
Matthias Endres
FIfor the RETRACE II (German‐Wide Multicenter Analysis of Oral Anticoagulation–Associated Intracerebral Hemorrhage II) Investigators
for the RETRACE II (German‐Wide Multicenter Analysis of Oral Anticoagulation–Associated Intracerebral Hemorrhage II) Investigators

1 January 2017 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
SLSebastian Luger
Sebastian Luger
JWJens Witsch
Jens Witsch
ADAndreas Dietz
Andreas Dietz
GHGerhard F Hamann
Gerhard F Hamann
JMJens Minnerup
Jens Minnerup
CFChristian Foerch
Christian Foerch
BACKGROUND: Recent studies have suggested that glial fibrillary acidic protein (GFAP) serum concentrations distinguish between intracerebral hemorrhage (ICH) and ischemic stroke (IS) shortly after symptom onset. In this prospective multicenter trial we validated GFAP in an independent patient cohort and assessed the quantitative relationship between GFAP release, bleeding size, and localization. METHODS: We included patients with a persistent neurological deficit (NIH Stroke Scale ≥4) suggestive of stroke within 6 h of symptom onset. Blood samples were drawn at hospital admission. GFAP serum concentrations were measured using an electrochemiluminometric immunoassay. Primary endpoint was the final diagnosis established at hospital discharge (ICH, IS, or stroke mimic). RESULTS: 202 patients were included (45 with ICH, 146 with IS, 11 stroke mimics). GFAP concentrations were significantly higher in ICH than in IS patients [median (interquartile range) 0.16 μg/L (0.04–3.27) vs 0.01 μg/L (0.01–0.01), P <0.001]. A GFAP cutoff of 0.03 μg/L provided a sensitivity of 77.8% and a specificity of 94.2% in distinguishing ICH from IS and stroke mimics [ROC analysis area under the curve 0.872 (95% CI, 0.802–0.942), P <0.001]. GFAP serum concentrations were positively correlated with ICH volume. Lobar ICH volumes were larger and thus associated with higher GFAP concentrations as compared to deep ICH. CONCLUSIONS: Serum GFAP was confirmed to be a biomarker indicating ICH in patients presenting with acute stroke symptoms. Very small ICH may be missed owing to less tissue destruction.